A Mab A Case | Study In Bioprocess Development !!top!!

: Minapharm Pharmaceuticals successfully implemented a two-step purification strategy for a mAb biosimilar. By using a mixed-mode resin (Nuvia aPrime 4A) in the polishing step, they eliminated an entire chromatography step. This approach significantly reduced production costs, process time, buffer consumption, and media costs , while increasing overall product yield .

The journey began with the selection of a Chinese Hamster Ovary (CHO) cell line expression system, specifically CHO-DG44.

The A-Mab study serves as a roadmap for applying guidelines to biotechnology.

Monoclonal antibodies have become a cornerstone of modern medicine, treating a wide array of diseases from cancers to autoimmune disorders. Their specificity and therapeutic efficacy have driven a significant market presence, with the global mAb market valued at over $200 billion annually. However, their complex structure—large, multi-subunit proteins requiring precise post-translational modifications—necessitates production in living systems. This biological complexity introduces significant variability, making the manufacturing process as critical to the drug's success as its molecular design. A Mab A Case Study In Bioprocess Development

| Parameter | Lab (2 L) | Pilot (50 L) | Commercial (2,000 L) | |-----------|-----------|--------------|----------------------| | Temp (°C) | 37 → 33 (shift) | Same | Same | | pH | 7.0 → 6.9 (shift) | Same | Same | | DO (%) | 40 | 40 | 40 | | Agitation (tip speed) | 0.3 m/s | 0.35 m/s | 0.45 m/s | | Sparger type | Microsparger | Microsparger | Ring + micro |

Shifting the temperature down slowed cell proliferation but prolonged cell viability and increased specific productivity (

[Day 0: Inoculation] ──> [Day 3: Feed Commences] ──> [Day 5: Temp Shift to 33°C] ──> [Day 14: Harvest] 3. Downstream Process Development The journey began with the selection of a

To achieve such results, the upstream development of A-mAb relies heavily on . Sophisticated mechanistic models are used to simulate the entire upstream process chain, from cell expansion to primary harvesting. These models predict the ideal initial seeding density and feeding rates to maximize growth and antibody production before they are validated in the lab. This data-driven approach significantly reduces the number of expensive, time-consuming "trial and error" experiments required.

Operated in flow-through mode. Achieved robust clearance of viral particles, DNA, and endotoxins.

The process demonstrated excellent scalability. The growth profile, viability, and CQA profiles at the 2,000 L scale closely mirrored the benchtop data, culminating in an overall final harvest titer of . 6. Conclusion and Future Directions Their specificity and therapeutic efficacy have driven a

Once the mAb is produced, it must be isolated and purified from the cell culture. Contentstack A–Mab: A Case Study in Bioprocess Development - ISPE 30 Oct 2009 —

Traditional mAb purification involves a step platform: capture with Protein A, followed by two polishing steps for impurity removal. However, several case studies highlight how this can be optimized or replaced for greater efficiency and lower cost.